Verona Pharma (VRNA) said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.
The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.
The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.
Verona Pharma shares were fractionally higher in recent Friday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。